Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jennifer S McGregor"'
Autor:
Pedro Luis Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S McGregor, Sailaja Puttagunta, Michael W Dunne
Publikováno v:
Drugs in Context, Vol 7, Pp 1-10 (2018)
Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, com
Externí odkaz:
https://doaj.org/article/3ecc525fb387486db854b4c900db82ae
Autor:
Pedro L. Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S. McGregor, Sailaja Puttagunta, Michael W. Dunne
Publikováno v:
Infectious Diseases and Therapy. 11:423-434
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f323a07c850688d01f0b547bfa8d454
https://doi.org/10.1007/s40121-021-00568-7
https://doi.org/10.1007/s40121-021-00568-7
Autor:
Karthik Akinapelli, Michael Nowak, Sailaja Puttagunta, Michael W. Dunne, Jennifer C. Nelson, Jennifer S McGregor, Veronica Mas Casullo, Pedro L Gonzalez, Urania Rappo
Publikováno v:
Infectious Diseases and Therapy
Introduction Dalbavancin is a lipoglycopeptide antibiotic approved as a single- and two-dose regimen for adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms. We present nephrotoxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ba403d576a16551ca22f04c88d8a9de
http://europepmc.org/articles/PMC7955009
http://europepmc.org/articles/PMC7955009
Autor:
Sailaja Puttagunta, Michael W. Dunne, Karthik Akinapelli, Pedro L Gonzalez, Urania Rappo, Jennifer S McGregor
Publikováno v:
Drugs in Context, Vol 7, Pp 1-10 (2018)
Drugs in Context
Drugs in Context
Background Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae8c68fd0e2b42a6c7182ff79f88069
https://www.drugsincontext.com/treatment-of-acute-bacterial-skin-and-skin-structure-infection-with-single-dose-dalbavancin-in-persons-who-inject-drugs
https://www.drugsincontext.com/treatment-of-acute-bacterial-skin-and-skin-structure-infection-with-single-dose-dalbavancin-in-persons-who-inject-drugs
Autor:
Yoav Golan, Pedro L Gonzalez, John Lock, Anathakrishnan Ramani, Julia Garcia Diaz, Jennifer S McGregor
Publikováno v:
Open Forum Infectious Diseases
Background Dalbavancin (DAL) is approved in the United States (US) and Europe for acute bacterial skin and skin structure infections and exhibits broad spectrum activity against clinically important Gram-positive pathogens including methicillin-sensi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d3724ea574b051a2b31a1ba7eeaf26f
https://doi.org/10.1093/ofid/ofaa439.1431
https://doi.org/10.1093/ofid/ofaa439.1431
Publikováno v:
Open Forum Infectious Diseases
Background Dalbavancin, a long-acting lipoglycopeptide approved by the US FDA and EMA for acute bacterial skin and skin structure infections (ABSSSI) has potent activity against Gram-positive pathogens including MRSA. A total of 39 of 39 patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f851e1d4b86532e75a60d814173dfa4
https://doi.org/10.1093/ofid/ofaa439.323
https://doi.org/10.1093/ofid/ofaa439.323
Autor:
Benjamin Georgiades, Jie Chen, Jennifer S McGregor, Matthew W. McCarthy, Pedro L Gonzalez, Urania Rappo
Publikováno v:
Open Forum Infectious Diseases
Background Dalbavancin is a lipoglycopeptide with activity against Gram-positive pathogens responsible for ABSSSI, including methicillin-resistant Staphylococcus aureus (MRSA), and is FDA-approved as a single- or two-dose regimen. The objective of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffdf9ee9da392e2a14b544e6e0051b11
http://europepmc.org/articles/PMC5631734
http://europepmc.org/articles/PMC5631734
Autor:
Jason Bryowsky, Michael Nowak, Pedro L Gonzalez, Urania Rappo, Jie Chen, David A. Talan, Jennifer S McGregor
Publikováno v:
Open Forum Infectious Diseases
Background ABSSSIs are common in patients with diabetes and have an increased risk of complications. Dalbavancin is a long-acting lipoglycopeptide with potent activity against Gram-positive pathogens responsible for ABSSSI, including methicillin-resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7cdc362bd695e612e4e24ff55f1b836
http://europepmc.org/articles/PMC5632173
http://europepmc.org/articles/PMC5632173